This live event will cover a broad spectrum of topics, including an overview and emerging trends of inhalation and respiratory drug products, formulation of inhaled therapies, digital health and patients’ perception, expectation, and intuitiveness in inhaled therapeutics.
Register today and request the brochure to discover scheduled Inhalation and respiratory drug topics.Read more
Register today and request the brochure to discover scheduled Inhalation and respiratory drug topics. This live event brings together experts from pharmaceutical and biotech industries and manufacturers, academia, and regulatory agencies, with the highest level of expertise in the respiratory field.
Chief Executives, Directors, Vice Presidents, Department Heads, Leaders, Senior Managers, Principal Scientists, Chemists and Engineers specializing in:
To request an agenda for this Summit, please complete the details below. We will send you the agenda via email.
Inhalation and respiratory drug development
Inhalation drug delivery
Diana A. Fernandes holds a MSc Degree in Biological Engineering by Instituto Superior Técnico, University of Lisbon, 2015. She joined Hovione in the same year as an Industrial PhD Candidate in collaboration with Faculty of Pharmacy, University of Lisbon, specializing in spray dried composite formulations for dry powder inhaler delivery of biopharmaceuticals, namely enzymes. Since 2018, Diana has also been working as an Inhaled Biopharmaceutical Formulation Scientist at Hovione R&D Drug Product Development Department, supporting the development and tech-transfer of Spray Drying and Jet Milling projects of inhalable clinical products ranging from small to large molecules, from lab to industrial scales.
She was one of the recipients of the prize for Women in Science at the 22nd Congress of the International Society for Aerosols in Medicine (ISAM), Montreux, Switzerland this year
Prof. Dr. Sven Stegemann is professor of patient-centric drug design and manufacturing at the Graz University of Technology, Austria. Sven has worked over the course of 22 years for Capsugel, acting as an advisor to major pharmaceutical companies on ways to improve the design, development and manufacture of pharmaceutical products so they better address the individual needs of patients. In his academic role, Sven focusses his research on the rational development of patient-centric drug products and their associated manufacturing technologies, as well as education and training of students and young scientists. He is the founder and chair of the AAPS focus group on patient-centric drug development, product design and manufacturing as well as the founder and president of the Geriatric Medicine Society e.V. He recently started the industrial-academic collaboration partnership Patient Centric Medicine (PaCeMe) to suitable and meaningful guidance for patient-centric drug product design. He is the editor of the book “Developing Drug Products in an Aging Society: From Concept to Prescribing”, a multidisciplinary approach towards patient-centric drug development for the older and multimorbid patient populations.
Mark is responsible for the Health Solutions within Digital Health at TEVA Pharmaceuticals. Over ten years with TEVA and prior to that, sixteen with AstraZeneca. Mark has held various positions, including R&D Project Leader, VP Sales & Marketing, Strategic Planning & Business Development, and Global Brand Lead. Graduated in Aeronautical Sciences and completed his MBA at Durham University, UK. During his career, he has led technology & especially inhaler development teams through engineering, CMC characterisation, clinical evidence generation, registration within US, EU, and International Markets and, ultimately, to successful global launch. Total Brand Leadership value >$2.5bn. Mark has numerous patents granted and pending in electronic communications, sports technologies, inhaled pharmaceutical development, and respiratory physiological function & predictive AI. Mark is the inventor of Digihaler®. The first FDA approved digital inhaler with built-in sensors.
Dr. Orest Lastow is the CTO of Iconovo AB. He is also the co-founder, former CEO of Iconovo. He is responsible for the development of Iconovo’s inhalation platforms. He is also the founder and previous CEO of the Medicon Valley Inhalation Consortium, MVIC AB. Orest was with AstraZeneca for over 15 years and is the principal inventor of AstraZeneca’s new dry powder inhalation platform. He is the author of a textbook on atomization, many journal publications, book contributions, and patent applications.
“Very interesting summit about inhalation and respiratory drug products in Vienna.”
"The presentations covered a wide range of topics and yet were all connected by our common research interests. I learned a great deal and appreciated this opportunity to participate in the 3rd Annual Inhalation & Respiratory Drug Products Summit. ”
“Beyond my expectations! It was very insightful experience thanks to all the knowledgeable speakers. “
Apr 20, 2018
2nd Annual Drug/Device Combination Products Summit